Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Transcatheter treatment of pure aortic regurgitation

Nature Reviews Cardiology volume 21, pages 597–598 (2024)Cite this article

Subjects

Preliminary experience with the use of transcatheter aortic valve implantation (TAVI) to treat non-calcific aortic regurgitation has raised concerns about the short-term effectiveness of TAVI in this setting. A deeper understanding of the interaction between transcatheter heart valves and anatomy in patients with non-calcific aortic valve disease, coupled with the introduction of dedicated TAVI devices, is providing new opportunities in the management of this condition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Distinct anchoring mechanisms of TAVI devices.

References

  1. Iung, B. et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 24, 1231–1243 (2003).

    Article  PubMed  Google Scholar 

  2. Carroll, J. D. et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 76, 2492–2516 (2020).

    Article  CAS  PubMed  Google Scholar 

  3. Yousef, A. et al. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation — a systematic review. Circ. J. 82, 895–902 (2018).

    Article  PubMed  Google Scholar 

  4. Roy, D. A. et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J. Am. Coll. Cardiol. 61, 1577–1584 (2013).

    Article  PubMed  Google Scholar 

  5. Yoon, S. H. et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J. Am. Coll. Cardiol. 70, 2752–2763 (2017).

    Article  PubMed  Google Scholar 

  6. Poletti, E. et al. Transcatheter aortic valve replacement for pure native aortic valve regurgitation: the PANTHEON international project. JACC Cardiovasc. Interv. 16, 1974–1985 (2023).

    Article  PubMed  Google Scholar 

  7. Elkasaby, M. H. et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement for pure aortic regurgitation: a systematic review and meta-analysis of 33,484 patients. BMC Cardiovasc. Disord. 24, 65–72 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mentias, A. et al. Transcatheter vs surgical aortic valve replacement in pure native aortic regurgitation. Ann. Thorac. Surg. 115, 870–876 (2023).

    Article  PubMed  Google Scholar 

  9. Vahl, T. P. et al. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet 403, 1451–1459 (2024).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Università degli Studi di Enna “Kore”, Enna, Italy

    Marco Barbanti & Giulia Laterra

  2. Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy

    Francesco Maisano

Authors
  1. Marco Barbanti
    View author publications

    Search author on:PubMed Google Scholar

  2. Giulia Laterra
    View author publications

    Search author on:PubMed Google Scholar

  3. Francesco Maisano
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Marco Barbanti.

Ethics declarations

Competing interests

M.B. is consultant for Boston Scientific, Edwards Lifesciences and Medtronic. F.M. declares grant or research institutional support from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, NVT, Terumo and Venus; has received consulting fees and honoraria (both personal and institutional) from Abbott, Cardiovalve, Edwards Lifesciences, Medtronic, Mtex, Occlufit, Simulands, Squadra, Valgen, Venus and Xeltis; has received royalty income from Edwards Lifesciences; and is shareholder (including share options) of 4Tech, Magenta and Transseptalsolutions. G.L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barbanti, M., Laterra, G. & Maisano, F. Transcatheter treatment of pure aortic regurgitation. Nat Rev Cardiol 21, 597–598 (2024). https://doi.org/10.1038/s41569-024-01059-1

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41569-024-01059-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing